The GA-map Dysbiosis Test is a clinically validated tool that characterises deviations in a patient’s gut microbiota relative to a healthy reference population, giving clinicians objective, reproducible insight to support the evaluation and management of gastrointestinal disorders such as IBS and IBD. CDD specialises in gastrointestinal disorders and is recognised for its expertise in faecal microbiota transplantation, making it a strategically relevant first foothold for Genetic Analysis in the Australian market.

“The launch at the Centre for Digestive Diseases is an important achievement for Genetic Analysis and a major step in bringing our microbiome diagnostic technology to Australia,” says Ronny Hermansen, CEO, Genetic Analysis.